It is currently Fri Jun 23, 2017 10:30 am

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Monoclonal Antibodies (mAbs)

Came across this article on monoclonal antibodies. Interesting to say the least.



Nature Biotechnology 23, 1025 (2005)
King in the kingdom of uncertainty

Monoclonal antibodies (mAbs) are not good drugs, at least they are not good drugs in any conventional sense. Many of the fundamental qualities of mAbs are just the sort of characteristics that used to make pharmaceutical manufacturers run a mile.

Most fundamentally, they are biological molecules and hence intrinsically ...
Read more : Monoclonal Antibodies (mAbs) | Views : 1938 | Replies : 0

On way back ? But fewer sales ??

Two articles of interest from The Boston Globe about Tysabri commercials.

Biogen Idec to seek stronger warning label for MS drug, CEO says
By Mark Jewell, AP Business Writer August 31, 2005

CAMBRIDGE, Mass. --The head of Biogen Idec Inc. said in an interview Wednesday his company will recommend to regulators within a month that the warning label be strengthened on a multiple sclerosis drug the company hopes to return to the market despite safety ...
Read more : On way back ? But fewer sales ?? | Views : 2398 | Replies : 2

Back late 05 or early 06?

A link to another Tysabri article. This one (like some others) considers that the treatment could be re-introduced in the US in late 05 or early 06.

Try some HarryZ - you know you want to! :lol:

Read more : Back late 05 or early 06? | Views : 2599 | Replies : 4

Tysabri Still Down, But Not Out

Market Scan
Tysabri Still Down, But Not Out
Matthew Herper, 08.09.05, 10:50 AM ET

Biogen Idec

After months of waiting, Biogen Idec (nasdaq: BIIB - news - people ) and Elan (nyse: ELN - news - people ) are finally having a good day--but investors should be careful not to be too exuberant about hopes for their beleaguered drug.

The two biotech firms have finished their safety review of Tysabri, the multiple sclerosis drug that ...
Read more : Tysabri Still Down, But Not Out | Views : 2300 | Replies : 0

Biogen, Elan sued for allegedly concealing MS drug risks

Biogen, Elan sued for allegedly concealing MS drug risks ... 1752087487

Biogen, Elan sued for allegedly concealing MS drug risks

Boston Business Journal

A patient is suing Biogen Idec and Elan Corp. PLC, accusing them of concealing risks of their multiple-sclerosis drug Tysabri before withdrawing it from the market.

Bloomberg News reported that the patient filed a federal court suit in San Francisco claiming both companies knew the ...
Read more : Biogen, Elan sued for allegedly concealing MS drug risks | Views : 1967 | Replies : 0

NEJM articles and editorial

Hi Everyone -

Thought I would point out that the New England Journal of Medicine out today has three articles following up on Tysabri and PML along with an editorial. I only get the abstracts and can't really tell what the key points are, but maybe one of you has better access or better insight into what is written.

- Arcee
Read more : NEJM articles and editorial | Views : 2151 | Replies : 3


Hot off the presses, folks! Here are the preliminary findings from the investigation into the Tysabri incidents.

This first one pertains to the poor woman who died:

Please read this one (above) carefully. MY question from reading this is: Did this woman even ever have MS at all??? Did the autopsy ever find lesions indicative of MS at all? Her neurological examination and symptom(s) presentation is/was almost exactly ...

Lawsuit: Similar Article - A Little More Detail

Here is another Boston Globe press release that just provides a tad bit more detail as to the allegations contained in the lawsuit against Biogen/Elan .

It almost sounds like me talking (a few months ago). How odd, huh? I will highlight.

Please also note below some clarification regarding "informed consent" (i.e. clinical "waivers") that I tried to explain many times in the past (very passionately, I might add), and which I just answered ...
Read more : Lawsuit: Similar Article - A Little More Detail | Views : 1901 | Replies : 1

Biogen sells factory

In today's Times (UK) the following appeared in the business pages:

'Biogen Idec, the US biotech company, sold a new factory to Genentech, a US rival for $408 million (£223 million). It was built to make Tysabri, the multiple sclerosis drug withdrawn amid brain disease fears'.

Perhaps this indicates that Biogen is not confident of the drug returning in the near future.

Read more : Biogen sells factory | Views : 2061 | Replies : 2


Login  •  Register


Total posts 238509 • Total topics 25973 • Total members 17238

Contact us | Terms of Service